Welcome back to Diagnosis, a vertical that focuses on the crossroads of health care policy and politics. ___ The financial toll of opioid use disorder in the U.S. reaches an estimated $934 billion per year, according to a report by Avalere Health. That figure includes lost productivity, health insurance and uninsured care costs, substance use treatment and criminal justice expenses. The report found total annual costs related to OUD to be $934 billion nationwide, with most of that, $438 billion, coming from lost employer productivity, followed by employee productivity, at $248 billion. OUD costs $111 billion annually in health insurance and uninsured costs, as well as $73 billion in lost household productivity. Other costs include criminal justice ($52 billion) and substance use treatment ($12 billion).  Opioid use disorder costs the U.S. $934 billion annually; treatment saves lives and money. The report emphasizes that access to effective treatment can significantly reduce these costs. Behavioral therapy alone can save up to $144,000 per case. When combined with long-acting injectable buprenorphine, savings rise to $295,000 — pairing behavioral therapy with methadone or sublingual buprenorphine results in savings of up to $271,000 per case. Roughly 6.1 million people reported having OUD in 2022. Defined as chronic opioid use causing significant distress or impairment, OUD is also linked to higher rates of financially motivated and violent crime, rates that decrease with effective treatment. Despite these benefits, barriers to care persist. These include provider stigma, insufficient training, geographic challenges, and the social stigma associated with seeking treatment. In Florida, OUD costs state and local governments between $200 and $299 per capita, which is comparable to about half the country. West Virginia faces the highest per capita cost, exceeding $500 per person. For context, the Centers for Disease Control and Prevention estimates the combined economic impact of heart disease and stroke at $422 billion, significantly less than even conservative estimates for OUD. Avalere's research drew from targeted literature and modeled OUD costs across outpatient care, including impacts on government, businesses, individuals and broader society. The report's research and writing team includes Margaret Scott as the principal, research scientist Tim Collins, senior associate Gina Krupp, associate Amanda Sitkowski, managing director Michael Ciarametaro, and associate principal Chani Seals. |
No comments:
Post a Comment